Top of page

Obinutuzumab with ibrutinib shows promise for mantle cell lymphoma

Published on: 17 January 2018

Encouraging results from the first part of the ongoing OASIS clinical trial.

Text that says Results

Results from the first part of the OASIS clinical trial show promise for a new treatment regimen for people with mantle cell lymphoma that has relapsed (come back) or was refractory (didn’t respond) to treatment.

The first part of the trial involved testing whether the combination of two targeted drugsobinutuzumab and ibrutinib, was safe and effective for people with relapsed or refractory mantle cell lymphoma. A total of nine people entered this part of the trial and there was a high response rate: eight people responded to the treatment with seven having a complete response (no evidence of lymphoma). The remaining participant’s lymphoma got worse during the trial. The side effects of the regimen were as expected.

The trial is continuing to recruit participants to test whether adding venetoclax to this combination can improve outcomes further.

Read more about the results of part 1 or find out more about the OASIS trial at Lymphoma TrialsLink.

‘The OASIS study is potentially very exciting in that combines three different drugs all which are active in mantle cell lymphoma and none of which are chemotherapy. This is the way treatments in this disease are likely to evolve over the next few years as we look to improve on the results we are seeing with ibrutinib’. 

Professor Simon Rule, Consultant Haematologist, Derriford Hospital, Plymouth